

# *Inclusivity* at the forefront of our clinical trials

Sanofi strives to make our clinical trials inclusive by design and partner with historically underrepresented communities to identify and address their unique needs.

Achievements as of June 2023, out of 22 U.S. trials<sup>1</sup>:

5%

of the clinical trials already achieved all 3 inclusivity targets

27%

of the clinical trials already achieved at least 2 inclusivity targets

45%

of the clinical trials have already achieved at least 1 inclusivity target

Inclusivity targets: Asian, Black, Hispanic. 1. With last patient in expected in 2023.



# Engaging our consumers *on our sustainable journey*

Nearly 70% of U.S. consumers are looking to buy sustainable products<sup>1</sup>

Products marketed as sustainable grew 2x faster than those that were not<sup>2</sup>

Reinforcing our brand-led impact for



*Sanofi Consumer Healthcare North America*



Large Consumer Healthcare company to be B Corp certified

**Certified**



This company meets high standards of social and environmental impact.

Corporation

1. Second "Business of Sustainability Index" by GreenPrint – 2023 report. 2. NYU Stern Center for sustainable business 2022 report (from 2013 to 2022), CPG market.

sanofi



ESG  
appendices





# Sanofi ESG Q2 *achievements*

## Affordable access



### Sanofi Global Health Unit

#Patients treated

Q1 2023	Q2 2023
<b>NCD</b> 54,396 19 countries	<b>NCD</b> 123,025 24 countries

#Active healthcare partnerships

13 partnerships 14 countries	25 partnerships 12 countries
---------------------------------	---------------------------------

#Impact Fund investments

1 investment	1 investment
--------------	--------------


### Rare disease vials donation

Q1 2023	Q2 2023
1,065 patients treated	1,073 patients treated
21,542 vials donated	52,407 vials donated

### Global access plan

Q1 2023	Q2 2023
6 global access plans initiated or developed covering more than 10 indications	6 global access plans initiated or developed covering more than 10 indications

## R&D for unmet needs



### Polio eradication

Q1 2023	Q2 2023
7 million IPV doses supplied to UNICEF	18.8 million IPV doses supplied to UNICEF

### Sleeping sickness elimination

FY 2021 <sup>1</sup>	FY 2022 <sup>1</sup>
2 million patients tested for HAT	1.5 million patients tested for HAT
805 patients treated	837 patients treated

### Pediatric cancer treatment development

Q1 2023	Q2 2023
2 assets in protocol preparation for clinical study	2 assets in protocol preparation for clinical study
	2 external collaboration contracts with the pediatric ITCC consortium established

Data in YTD unless stated otherwise. 1. Data provided by WHO.

# Sanofi ESG Q2 *achievements*

## Planet care



### Blister-free syringe vaccines

FY 2022	FY 2023
<b>33%</b> of blister free syringe vaccines produced	Data updated annually at Q4 2023

### Eco-design

Q1 2023	Q2 2023
<b>7</b> LCAs completed & <b>4</b> in progress (new products and marketed product) <sup>1</sup>	<b>7</b> LCAs completed & <b>4</b> in progress (new products and marketed product) <sup>1</sup>

### Scope 1 & 2 GHG emissions reduction

Q1 2023	Q2 2023
<b>-30.5%</b> vs. 2019	<b>-32.6%</b> vs. 2019

### Renewable electricity & eco-car fleet

Q1 2023	Q2 2023
<b>62.6%</b> renewable electricity	<b>67.2%</b> renewable electricity
<b>34.9%</b> eco-fleet	<b>36.5%</b> eco-fleet

## In and beyond the workplace



### Diverse Senior Leadership

Q1 2023	Q2 2023
<b>37.5%</b> of our executives and <b>42.1%</b> of our senior leaders were women	<b>38.0%</b> of our executives and <b>42.4%</b> of our senior leaders were women

### Engagement with communities

FY 2022	Q2 2023
<b>4,975</b> volunteers	<b>2,883</b> volunteers
<b>26,906</b> hours	<b>18,103</b> hours

### From Leaders to Citizens

Q1 2023	Q2 2023
<b>65%</b> of the leaders have completed the eLearning phase	<b>68%</b> of the leaders have completed the eLearning phase
<b>9%</b> of the leaders have completed the full program	<b>12%</b> of the leaders have completed the full program

Data in YTD unless stated otherwise. 1. Since 2019.

# Sanofi ESG ratings

## Rating agencies

<b>SCORE</b>	<b>SCORE</b>	<b>SCORE</b>	<b>SCORE</b>	<b>SCORE</b>	<b>SCORE</b>	<b>SCORE</b>	<b>SCORE</b>	<b>SCORE</b>
<b>86/100</b>	<b>21.5 Medium risk</b>	<b>71/100</b>	<b>A</b>	<b>Climate Change: A Water: A-</b>	<b>B</b>	<b>4.5/5</b>	<b>3.47/5</b>	<b>65/100</b>
New rating done in 2022	▼ 21.2	▲ 70/100	= A	= ▼ A/A	= B	▲ 4.3/5	= 3.47/5	▲ 64/100
One of the highest scores across all sectors globally 80 points for its solid fundamentals & strong preparedness opinion of 6 points	11 <sup>th</sup> among 433 pharmaceutical companies	Percentile of 97 within 156 scored companies in the industry	Within the top 6 highest rated pharmaceutical companies	Leading position	1 <sup>st</sup> decile of the 476 companies in the industry	With very high rating across the 3 pillars ESG	Top 10 company	1 <sup>st</sup> pharmaceutical company out of 57 Score improving since 2018

▲ vs. previous rating

Scores assigned by the rating agencies are not equivalent.